Navigation Links
Immunosyn Corporation Files 10-Q
Date:5/16/2008

LA JOLLA, Calif., May 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending March 31, 2008.

For the quarter ended March 31, 2008, the company incurred $175,632.00 in general and administrative expenses and $13,393.00 in interest expense which was funded from advances by affiliates of $179,798.00, accounts payable of $32,249.00 and accrued expenses of $12,151.00. As a result, the company had a Net Loss of $189,025.00 for the first quarter of 2008. During the same period in 2007, the company incurred $162,714.00 in general and administrative expenses and interest expense of $3,714.00 and had a Net Loss of $166,428.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.

"We have continued to significantly control costs this quarter and appreciated the advances from affiliates," noted Stephen Ferrone, Immunosyn's CEO. "In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC," added Ferrone.

Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating di
'/>"/>

SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
3. Immunosyn Announces Interview of CEO Stephen D. Ferrone by CEOCFO Interviews & News
4. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
5. Immunosyn Corporation Names G. David Criner as CFO
6. Immunosyn Corporation to Present at FSX
7. CorVel Corporation Announces Earnings Release Webcast
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
10. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Global Stem Cells Group today ... annual gathering of aesthetic medicine experts and innovators. GSCG ... introduce the company’s brand new training course that combines ... techniques. , The course is designed to address ... field, including facial aging caused by volume loss. ...
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... today announced that it has received approval from ... of 5,126,044 outstanding common share purchase warrants ("the ... connection with the Company,s May 2013 private placement ...
(Date:4/17/2015)... Global Stem Cells Group has announced ... April 27 - 29, 2015 in Boston. This world-class ... of stem cell research including applications, biology, medicine, regulations, ... , The conference will address recent developments in ... in stem cell therapies, regenerative medicine, tissue engineering, stem ...
Breaking Biology Technology:Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3
... 2 or 3 patients achieve undetectable HCV RNA levels, following 4 weeks of treatment with ... ... with Pegasys ... plus Copegus -, PRINCETON, N.J., Sept. 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces ...
... Whalen as Solutions Director. , ... ... [Symphony Management Consulting] announced that it has appointed A.J. Whalen ... from Wellesley Information Services (WIS) where he was responsible for ...
... helps visitors to electronica 2008 in Munich and covers topics such ... sources of pre-show information useful in planning a trip, online registration ... an extensive list of web links to travel, hotel, city and ... ...
Cached Biology Technology:Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6Symphony Managemnt Consulting Hires New Solutions Director 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 2Free White Paper Now Available: How to get the most from your visit to electronica 2008 in Munich 3
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... Immediate Release,Wednesday, October 28, 2009 Contact:,Robin Mackar, NIEHS,(919) ... Bisph Researchers studying the health effects of the chemical ... an integrated research initiative to produce data that will ... health effects. Researchers who just received funds ...
... 2009) Paved parking lots and driveways make our lives ... to reach underground water sources and alter the natural flow ... Agency today announced a study that will investigate ways to ... how water filters back into the ground. EPA is testing ...
... identified wheat and barley lines resistant to Crown Rot ... million in lost yield every year. Crown Rot, which ... caused by the fungus Fusarium . Dr Chunji ... using sophisticated screening methods to scan over 2400 wheat lines ...
Cached Biology News:NIEHS awards Recovery Act funds to address bisphenol A research gaps 2NIEHS awards Recovery Act funds to address bisphenol A research gaps 3NIEHS awards Recovery Act funds to address bisphenol A research gaps 4NIEHS awards Recovery Act funds to address bisphenol A research gaps 5NIEHS awards Recovery Act funds to address bisphenol A research gaps 6NIEHS awards Recovery Act funds to address bisphenol A research gaps 7NIEHS awards Recovery Act funds to address bisphenol A research gaps 8EPA's new green parking lot allows scientists to study permeable surfaces that may help the environment 2
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... Yellow crystalline solid. PROTECT FROM LIGHT. Useful in cell ... Purity: ≥98% by TLC. Soluble in DMSO ... of a 10 mM stock in DMSO is recommended. ... H 2 O with rapid mixing (e.g. 10 μl ...
Biology Products: